GHK-Cu Dosage, Injections and Side Effects

The short answer: topical GHK-Cu has decades of cosmetic use and a small set of human trials behind it. Injected GHK-Cu has no published human dosing study at all. The injection doses passed around online are not taken from any trial in people. FDA's main stated concern with the injectable form is immune reactions from clumped peptide and impurities, and it says there are "limited data in humans" to judge safety⁹.

So the honest dosing answer depends entirely on the route. Here is what each route rests on, where the injection numbers come from, what the side-effect record actually shows, and where the injectable form stands with FDA.

Topical vs injection: two different evidence bases

GHK is a three-amino-acid peptide found naturally in human blood that binds copper tightly; GHK-Cu is that copper complex. In cell and animal work it increases collagen and other skin-building molecules, and supports blood vessel and nerve growth¹. In a classic rat study it drove connective tissue build-up in wounds². Reviews of its skin biology describe a consistent repair-and-renewal picture³.

The human trials are all topical, and there are only a few of them.

• •Diabetic foot ulcers (1994). In a multicenter, randomized, placebo-controlled trial, a GHK-Cu gel applied daily alongside standard wound care closed plantar ulcers more completely than the plain gel: a median 98.5% versus 60.8% closure⁴.
• •Laser-resurfaced skin (2006). In a randomized study of 13 patients after facial laser treatment, GHK-Cu skin care made no measurable difference to redness, wrinkles or skin quality by blinded assessment. Patients using it reported higher satisfaction⁵.
• •Anti-wrinkle use. A 2025 review of topical GHK concluded that its effect is clear in cells, but noted "a surprising absence of clinical studies" for the GHK-Cu products sold for wrinkles, and limited data on how well it gets through skin at all⁶.

That is the whole human record. None of it involved an injection.

Where injectable doses come from

Injection protocols online usually quote a milligram or two under the skin daily, in cycles of several weeks. No human study supports that number, or any other.

The closest animal data used different routes and settings:

• •Rat knee surgery. Rats given GHK-Cu injected directly into the knee joint, once a week for four weeks after ligament reconstruction, showed a better result at six weeks that had disappeared by twelve⁷. That is a local injection into one joint, not a body-wide dose.
• •Mouse burns. GHK-Cu packed into liposomes and applied to scalded mouse skin sped wound healing and blood vessel growth⁸. Again, applied where the injury was.

Much of what GHK-Cu does in the research happens where it is placed. A shot under the skin of the belly to fix a sore shoulder or improve your face assumes a body-wide effect that no study has measured. If a seller gives you a precise injectable dose, ask what study it came from. There isn't one.

Side effects: what is recorded and what is not

Topical. In the controlled topical trials above, GHK-Cu gel and skin care were used without safety problems serious enough to feature in the published results. The ulcer trial even reported fewer infections in the treated group⁴. Those were small studies, so rare skin reactions would not show up.

Injected. No human trial has reported on injected GHK-Cu. What FDA says about the compounded injectable form is specific: it "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities"⁹. Immunogenicity means the body reacting to the injected product as foreign, from injection-site reactions up to allergy. Add the usual risks of any home injection: pain, redness, and infection if the vial or technique is not sterile.

Copper load. The copper is real, and it is worth doing the arithmetic. Copper makes up roughly 15% of the weight of the GHK-Cu complex. A 2 mg injection therefore carries about 0.3 mg of copper, about a third of the adult daily recommended intake of 900 micrograms¹². That is not a toxic amount for most people. But it bypasses the gut, which normally regulates how much copper gets in, and it adds up over a daily cycle. People with Wilson disease or other copper-handling conditions should not be injecting extra copper at all.

Regulatory status

GHK-Cu as a cosmetic ingredient is unaffected by any of this. The injectable form is a different matter.

• •Where it sits. FDA lists "GHK-Cu (for injectable routes of administration)" in its table of bulk substances whose compounding nominations were withdrawn⁹.
• •How it got there. It moved out of FDA's live safety-risk list (category 2) in the page revision dated April 22, 2026, one of twelve peptides that moved that day⁹¹⁰. Moving tables is a procedural change, not a safety clearance.
• •What it means. GHK-Cu is not on the 503A list of substances pharmacies may compound¹¹, and it was not among the substances FDA put to its advisory committee in July 2026¹³. There is no lawful compounding route for injectable GHK-Cu today.

The status of every peptide in this category is kept on our peptide regulatory tracker.

What telehealth menus actually sell

Prescription menus mostly carry GHK-Cu as a cream or a troche, and the format tells you more than the marketing. Andrew Meds sells a GHK-Cu cream at $79, with a lower tier at $49, and its savings figures reconcile to the dollar. FORM by GBY sells a GHK-Cu cream but publishes no price for it, while pricing its GLP-1 line to the dollar. Bodybuilding Health+ kept a topical GHK-Cu after cutting its research-peptide line in 2026. LaSara Medical Group sells GHK-Cu as fifteen troches for $140, dissolved in the mouth, a route no GHK-Cu trial has tested, and bills it monthly though fifteen troches is not a month at one a day. Live Vital lists GHK-Cu at $99 a month but publishes no strength or vial size for any product, so you cannot tell what dose that buys.

Blends multiply the unknowns

GHK-Cu is also the anchor of pre-mixed injectable blends, sold with BPC-157 and TB-500 in one vial as "GLOW," with KPV added as "KLOW." Each extra compound brings its own missing dose data, and nobody has tested the combinations in people. If a single-ingredient GHK-Cu injection has no validated dose, a blend has three or four unvalidated doses in fixed ratios you cannot adjust. We go through what has been tested in the GLOW peptide blend and the KLOW blend.

What to ask before you buy

1. 1.Which route, and why? If the goal is skin, the route with human data is topical. Ask why an injection or troche would do better.
2. 2.What strength is in the product? A cream, troche or vial with no stated amount cannot be dosed, whatever the instructions say.
3. 3.Who compounds it? For anything injectable, ask the name of the pharmacy and the legal basis, since injectable GHK-Cu is not on the 503A list.
4. 4.Do you have a copper-handling condition, or take copper supplements? Injected copper adds to everything else you take in.

The bottom line

If you want GHK-Cu for skin, the topical form is the one with human data, modest as it is⁴⁵. If you are considering injections, there is no validated dose, no human safety trial, an FDA immunogenicity warning⁹ and no lawful compounding route today. For what GHK-Cu can and cannot do for recovery, see GHK-Cu for recovery and skin: the evidence. If what you want is a peptide a clinician can prescribe and a licensed pharmacy can fill now, our recovery peptide rankings compare the providers on price and terms.